Premium
The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma
Author(s) -
Davies Joanna M.,
Osborne Thomas R.,
Edmonds Polly M.,
Schey Steve A.,
Devereux Steve,
Higginson Irene J.,
Ramsenthaler Christina
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12864
Subject(s) - medicine , quality of life (healthcare) , discriminant validity , construct validity , follicular lymphoma , multiple myeloma , scale (ratio) , patient reported outcome , population , confirmatory factor analysis , physical therapy , lymphoma , psychometrics , clinical psychology , internal consistency , nursing , statistics , physics , environmental health , quantum mechanics , structural equation modeling , mathematics
Abstract Objectives The development of novel agents and an ageing population has led to an increasing number of patients with follicular lymphoma ( FL ) living longer with their disease. Health‐related quality of life ( HRQOL ) is a priority for patients and should guide clinical decisions. The Myeloma Patient Outcome Scale (My POS ), originally developed for myeloma, was validated in a cross‐sectional survey recruiting 124 FL patients. Methods Content and construct validity, structural validity using confirmatory factor analyses, reliability and acceptability were evaluated. Results Three subscales were indicated: symptoms and function, emotional response, and healthcare support. My POS symptom and function scores were higher (worse) in participants with poorer ECOG performance status ( F =26.2, P <.000) and discriminated between patients on and off treatment. Good convergent and discriminant validity in comparison to the EORTC ‐ QLQ ‐C30 and FACT ‐Lym were demonstrated. Internal consistency was good; α coefficient 0.70‐0.95 for the total My POS score and subscales. Conclusion The My POS is valid, reliable and acceptable, and can be used to support clinical care of FL patients. This is the first measurement tool developed specially for use in clinical practice that has been validated for use in people with FL . Further longitudinal validation is now required to support its use in outcome measurement.